
ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a селективный dopamine D3 рецептор (DRD3) антагонист with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a селективный dopamine D₃ рецептор антагонист with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.
ABT-925, also known as A-37203, BSF-201640; DAT-201; Lu-201640; and A-437203, is a selective dopamine D3 receptor (DRD3) antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors. ABT-925 was tested in schizophrenia. ABT-925 is a selective dopamine D₃ receptor antagonist with an approximately 100-fold higher in vitro affinity for dopamine D₃ versus D₂ receptors.
Только для научно-исследовательского применения. Не предназначено для использования у пациентов или в качестве лекарственного средства.